hi Vanessa,
dasatinib (Sprycel) is licenced and available in most parts of the UK for use in Glivec resistant/intolerant chronic stage CML.
however it has not yet had a NICE appraisal so some regional health authorities have taken the view that they can therefore refuse funding for this therapy. the regions that are problematic are in the minority and only in some parts of England ... not in Scotland or Wales.... therefore access to dasatinib would depend on where you chose to live should you return to the UK.
nilotinib (Tasigna) is only available within the ENACT trial programme which ends in April.
However, both drugs are due to be approved for an appraisal by NICE. this process will take some time but we hope to have a positive decision for both drugs by mid 2009. this means they will then be available on NHS prescription throughout the UK.
Sandy